Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

ADT beneficial for prostate cancer patients with unfavorable intermediate risk

Key clinical point: Androgen deprivation therapy (ADT) lowers risk for distant metastasis and cancer-specific mortality in unfavorable intermediate-risk patients with prostate cancer compared with no ADT use.

Major finding: In patients with unfavorable intermediate risk, the use of ADT significantly decreased the risk for distant metastasis (hazard ratio [HR], 0.48; P = .008) and cancer-specific mortality (HR, 0.40; P less than .001).

Study details: The data come from a secondary analysis of RTOG 9408 trial involving 890 patients with intermediate-risk prostate cancer who received radiotherapy with or without 4 months of ADT.

Disclosures: The study was funded by National Cancer Institute. ZS Zumsteg, DE Spratt, TJ Daskivich and H Sandler reported ties with various pharmaceutical companies.


Zumsteg ZS et al. JAMA Netw Open. 2020 Sep 9. doi: 10.1001/jamanetworkopen.2020.15083.